rBaltMIP, a recombinant alpha-type myotoxin inhibitor from Bothrops alternatus (Rhinocerophis alternatus) snake, as a potential candidate to complement the antivenom therapy
We evaluated rBaltMIP as a complement of conventional antivenom therapy. rBaltMIP was more effective in inhibiting muscle damage than the antivenom. rBaltMIP injection did not elicit the production of anti-rBaltMIP antibodies in mice. rBaltMIP has promising use as a phospholipase A2 inhibitor in antivenom therapy.